Concert Pharmaceuticals has assembled a balanced investor base which includes top-tier venture capital and leading crossover funds. The Company has been financed by:
- Brookside Capital Partners Fund
- TVM Capital
- Three Arch Partners
- Fidelity Investments
- Skyline Ventures
- Flagship Ventures
- Adage Capital Management
- Greylock Partners
- New Leaf Venture Partners
- QVT Fund
- SR One Ltd. (GlaxoSmithKline's healthcare venture fund)
- Mediphase Venture Partners
- Westfield Capital Management
- Alexandria Equities, LLC
TVM Capital, founded in 1983, is a transatlantic venture capital firm, with offices in Boston and Munich. Since inception TVM Capital has raised over $1.6 billion in six fund generations and has established itself as a leading technology investment group in the United States and Europe. TVM funds have made investments in more than 220 life sciences and information technology companies where innovation, effective management and sound financial backing have enormous impact on company growth. TVM’s in-depth knowledge of the U.S. and European environments helps companies create businesses that enjoy access to science, management talent, distribution channels and capital on both sides of the Atlantic. More than 40 companies have gone public at European or US stock exchanges. Today, TVM Capital is actively invested in more than 60 companies.
Three Arch Partners
Three Arch Partners was formed in 1993 to provide young companies with access to relevant clinical and business resources, as well as capital. Three Arch has helped create, build and fund more than fifty important new healthcare companies. These companies have often become the clinical and market leaders in their respective fields, and have generated strong returns.
Skyline Ventures, formed in 1997, is a nationally-known firm that specializes in hands-on investing in healthcare companies. Skyline invests in outstanding companies in all sectors of the healthcare market, including biotechnology, small molecule and protein therapeutics, medical devices, consumables and equipment for life sciences research, and healthcare information technology. Most often they lead or co-lead a company's first institutional venture round, but occasionally have helped found or co-found a company, participated in a LBO or invested in a PIPE transaction. In 2005 Skyline raised Skyline IV, which has $200 million in committed capital, leading to a total of approximately $450 million under management. In October 2007, Skyline completed raising Skyline V, which has $350 million in committed capital. Skyline has approximately $800 million under management.
Flagship Ventures is an early-stage venture capital firm focused on creating, financing, and building innovative companies in the Life Science and Technology sectors. Headquartered in Cambridge, Mass., the firm was founded in 1999 and manages $700 million in capital and a portfolio of over 50 private companies.
Greylock Partners’ strategy is to partner with management in building companies that have the potential to become industry leaders. They prefer to build around an outstanding entrepreneurial leader or team with a powerful technology and market vision. Greylock tends to focus on capital-efficient businesses where high barriers to entry can be constructed, and works closely with the start-up team to build the organization. Greylock currently has committed capital in excess of $2 billion.
New Leaf Venture (NLV) Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded by the former members of Sprout Group's Healthcare Technology venture team, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices, and molecular diagnostics. NLV Partners manages over $1.3 billion of assets, including NLV-I, NLV-II and the healthcare technology portfolio of Sprout Group. In addition, the NLV Partners team continues to manage the existing $800 million healthcare technology portfolio of Sprout Group.
Mediphase Venture Partners
Mediphase Venture Partners is a venture capital firm focusing on companies in the areas of biopharmaceutical technology and life sciences information. Mediphase seeks companies which can achieve rapid product development and customer revenue, which are efficient in use of capital, and which have strong intellectual property positions. The Mediphase partners are active investors, usually joining the Boards of their portfolio companies and working closely with management to promote rapid growth. The Fund managers bring an unusual combination of technical experience, operating experience, and investment experience, which can be critical to the success of an early stage company.
Alexandria Equities, LLC
Alexandria Equities, LLC is the strategic investment entity of Alexandria Real Estate Equities, Inc. (ARE: NYSE). Alexandria Equities, LLC provides important and significant capital to the broad and diverse life science sector.
[ back to top ]